REG - ABCAM Plc - Director/PDMR Shareholding
For best results when printing this announcement, please click on the link below:
http://pdf.reuters.com/Regnews/regnews.asp?i=43059c3bf0e37541&u=urn:newsml:reuters.com:20100329:nRSc3606Ja
RNS Number : 3606J
ABCAM Plc
29 March 2010
For immediate release 29 March 2010
29 March 2010
ABCAM PLC
("Abcam" or "the Company")
PDMR Dealings
Cambridge, UK: Abcam plc (AIM: ABC), the rapidly growing bioscience company that markets antibodies via its own online
catalogue, has today been notified of the following transactions under the Abcam plc Share Incentive Plan ("the SIP") to
the benefit of the PDMRs:
Name Partnership Shares purchased on 26 March 2010 at 1215 pence per share Matching Shares awarded on 26 March 2010 at 1215 pence per share Subsequent Beneficial Interest in the Company Subsequent percentage holding of issued share capital
Mark Bushfield 11 11 73 0.0002%
Philippe Cotrel 10 10 343 0.0010%
0.0002%
Philippe Cotrel
10
10
343
0.0010%
The risk of forfeiture attached to the Matching Shares will normally be removed on the third anniversary of the award
subject to continued employment and the retention of the Partnership Shares in connection with which they were awarded. No
consideration was paid by the above grantees for the award of the Matching Shares and no consideration is due on their
release.
The Company has also been notified that on 29 March 2010, Jane Cooke, a PDMR of the Company, exercised share options over
5654 ordinary shares of 1 pence each in the Company at an exercise price of 280p per share. Following this transaction, Mrs
Cooke's total beneficial interest in the Company is 9551 ordinary shares representing approximately 0.03 per cent. of the
current issued share capital of the Company.
For further information please contact:
Abcam + 44 (0) 1223 696000
Jonathan Milner, Chief Executive Officer
Jeffrey Iliffe, Chief Financial Officer
Numis Securities + 44 (0) 20 7260 1000
Michael Meade / Nick Westlake - Nominated Adviser
James Black - Corporate Broking
Buchanan Communications + 44 (0) 20 7466 5000
Mark Court / Stasa Filiplic
Buchanan Communications
+ 44 (0) 20 7466 5000
Mark Court / Stasa Filiplic
Notes for editors:
About Abcam plc
Abcam is a producer and distributor of research-grade antibodies headquartered in Cambridge, United Kingdom, with
subsidiaries in Cambridge, Massachusetts, Tokyo and Hong Kong. Abcam was admitted to AIM in November 2005 and trades under
the ticker symbol ABC. The Company produces and distributes its own and third-party produced antibodies and related
products to academic and commercial users throughout the world. Product ordering is available through the Company's website
www.abcam.com, where customers are also able to access up-to-date and detailed technical product data sheets. All the
antibodies are sold under the Abcam brand name. Abcam's mission is to develop the largest catalogue of the best antibodies
in the world, with the vision of becoming a global leader in the wider protein detection and regulation markets. Abcam now
has a rapidly growing online catalogue and as at 31 December 2009 it contained 57,960 products, most of which are
antibodies, from over 250 suppliers. Abcam employs 250 staff in its four operating companies.
This information is provided by RNS
The company news service from the London Stock Exchange
back to RNS news